TY - T1的过度使用短效β2 <子> < /苏b>-agonists in asthma is associated with increased risk of exacerbation and mortality: A nationwide cohort study of the global SABINA programme JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01872-2019 SP - 1901872 AU - Nwaru, Bright I. AU - Ekström, Magnus AU - Hasvold, Pål AU - Wiklund, Fredrik AU - Telg, Gunilla AU - Janson, Christer Y1 - 2020/01/01 UR - //www.qdcxjkg.com/content/early/2019/12/12/13993003.01872-2019.abstract N2 - Background Overuse of short-acting β2 agonists (SABA) may indicate poor asthma control and adverse health outcomes. Contemporary population-based data on use, risk factors and impact of SABA (over)use on asthma exacerbations and mortality are scarce, prompting initiation of the global SABINA (SABA use IN Asthma) programme.Methods By linking data from Swedish national registries, asthma patients aged 12–45 years with ≥2 collections of drugs for obstructive lung disease during 2006–2014 were included. SABA overuse defined as collection of >2 SABA canisters in a one-year baseline period following inclusion. SABA use was grouped into 3–5, 6–10 and 11+ canisters/baseline-year. Cox regression was used to examine associations between SABA use and exacerbation (hospitalisations and/or OCS claims) and mortality.Results The analysis included 365 324 asthma patients (mean age 27.6 years; 55% women), average follow-up was 85.4 months. Some 30% overused SABA, with 21% collecting 3–5 canisters, 7% 6–10 and 2% 11+ canisters·year−1. Increasing number of collected SABA canisters was associated with increased risk of exacerbation: 3–5 (HR 1.26; [95% CI] 1.24–1.28); 6–10 (1.44; 1.41–1.46); and 11+ canisters (1.77; 1.72–1.83) compared to ≤2 canisters·year−1. Higher SABA use was associated with incrementally increased mortality risk (2564 deaths observed): 3–5 (HR 1.26; 95% CI 1.14–1.39); 6–10 (1.67; 1.49–1.87); and 11+ canisters (2.35, 2.02–2.72) compared to ≤2 canisters·year−1.Conclusion One-third of asthma patients in Sweden collected three or more SABA canisters annually. SABA overuse was associated with increased risks of exacerbation and mortality. These findings emphasise that monitoring of SABA usage should be key in improving asthma management.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr Nwaru reports personal fees from AstraZeneca, during the conduct of the study.Conflict of interest: Dr Ekström reports personal fees from AstraZeneca, during the conduct of the study.Conflict of interest: Dr Hasvold reports other from AstraZeneca, during the conduct of the study.Conflict of interest: Dr Telg reports personal fees from Employed by AZ, during the conduct of the study.Conflict of interest: Dr Christer Janson[AQ2] Conflict of interest: Dr Wicklund reports other from Statisticon/AstraZeneca, during the conduct of the study. ER -